Inhibition of nuclear factor-κB activity enhanced chemosensitivity to cisplatin in human lung adeno-carcinoma A549 cells under chemical hypoxia conditions

Chinese Medical Journal

Volumn 126, Issue 17, 2013, Pages 3276-3282

  Li, Fang ^a   Huang, Li ^a   Su, Xiao Li ^a   Gu, Qi Hua ^a   Hu, Cheng Ping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Bcl 2; Chemical hypoxia; Chemotherapy; Lung adenocarcinoma; Nuclear factor B

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CISPLATIN; COBALT CHLORIDE; FLUORESCEIN ISOTHIOCYANATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; PROTEIN BCL 2; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HYPOXIA; IC 50; IMMUNOFLUORESCENCE TEST; LUNG ADENOCARCINOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOCARCINOMA; ANOXIA; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; HUMANS; LUNG NEOPLASMS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84883502423     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20123391     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Rajeswaran A, Trojan A, Burnand B, Giannelli M. Efficacy and side effects of cisplatin-and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small celllungcarcinoma: a systematic review of randomized controlled trials. Lung Cancer 2008; 59: 1-11.
3. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med 2005; 172: 523-529.
4. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. J Cancer Treat Rev 2003; 29: 297-307.
5. Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. Tumor hypoxia: a target for selective cancer therapy. J Cancer Sci 2003; 94: 1021-1028.
6. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. J Clin Cancer Res 2010; 16: 5928-5935.
7. Chaudary N, Hill RP. Hypoxiaandmetastasis. Clin Cancer Res 2007; 13: 1947-1949.
8. Fan C, Li Q, Ross D, Engelhardt JF. Tyrosine phosphorylation of IκBα activates NFκB through a redox-regulated and c-Src-dependent mechanism following hypoxia/reoxygenation. J Biol Chem 2003; 278: 2072-2080.
9. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. J Ann Rev Immunol 2000; 18: 621-663.
10. Takahashi Y, Ganster RW, Gambotto A, Shao L, Kaizu T, Wu T, et al. Role of NF-kappaB on liver cold ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol 2002; 283: G1175-G1184.
11. Pham LV, Tamyo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-κB activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171: 88-95.
12. Shishodia S, Aggarwal BB. Nuclear factor-kappaB activation: a question of life or death. J Biochem Mol Biol 2002; 35: 28-40.
13. Mattson MP, Meffert MK. Roles for NF-kappaB in nerve cell survival, plasticity, and disease. J Cell Death Differ 2006; 13: 852-860.
14. Qanungo S, Wang M, Nieminen AL. N-acetyl-L-cysteine enhances apoptosis through inhibition of nuclear factor-kB in hypoxic murine embryonic fibroblasts. J Biol Chem 2004; 279: 50455-50464.
15. Madonna G, Ullman CD, Gentilcore G, Palmieri G, Ascierto PA. NF-κB as potential target in the treatment of melanoma. J Transl Med 2012; 10: 53.
16. Zhang D, Qiu L, Jin X, Guo Z, Guo C. Nuclear factor-kappaB inhibition by parthenolide potentiates the efficacy of Taxol in non-small cell lung cancer in vitro and in vivo. J Mol Cancer Res 2009; 7: 1139-1149.
17. Campbell KJ, Rocha S, Perkins ND. Active repression of antiapoptotic gene expression by RelA (p65) NF-kappaB. J Mol Cell 2004; 13: 853-865.
18. Ho WC, Dickson KM, Barker PA. Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. J Cancer Res 2005; 65: 4273-4281.
19. Lee BL, Lee HS, Jung J, Cho SJ, Chung HY, Kim WH, et al. Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer. J Clin Cancer Res 2005; 11: 2518-2525.
20. Qiao L, Zhang H, Yu J, Francisco R, Dent P, Ebert MP, et al. Constitutive activation of NF-kappa B in human hepatocellular carcinoma: evidence of a cytoprotective role. J Hum Gene Ther 2006; 17: 280-290.
21. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, et al. NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α. Nature 2008; 453: 807-811.
22. Mishra DK, Sakamoto JH, Thrall MJ, Baird BN, Blackmon SH, Ferrari M, et al. Human lung cancer cells grown in an ex vivo 3D lung model produce matrix metalloproteinases not produced in 2D culture. PLoS One 2012; 7: e45308.
23. Meike S, Yamamori T, Yasui H, Eitaki M, Matsuda A, Inanami O. 8-Aminoadenosine enhances radiation-induced cell death in human lung carcinoma A549 cells. J Radiat Res 2011; 52: 456-463.
24. Karovic O, Tonazzini I, Rebola N, Edström E, Lövdahl C, Fredholm BB, et al. Toxic effects of cobalt in primary cultures of mouse astrocytes: similarities with hypoxia and role of HIF-1α. J Biochem Pharmacol 2007; 73: 694-708.
25. Nardinocchi L, Puca R, Sacchi A, D'Orazi G. Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-correlates with sensitization of chemoresistant cells to undergo apoptosis. J Mol Cancer 2009; 7: 4018-4021.
26. Zhang MC, Hu CP, Chen Q. Effect of down-regulation of survivin gene on apoptosis and cisplatin resistance in cisplatin resistant human lung adenocarcinoma A549/CDDP cells. Chin J Oncol (Chin) 2006; 28: 408-412.
27. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. Emerging Bcl-2 inhibitors for the treatment of cancer. J Expert Opin Emerg Drugs 2011; 16: 59-70.
28. Castro-Gamero AM, Borges KS, da Silva Silveira V, Lira RC, de Paula Gomes Queiroz R, Valera FC, et al. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells. J Anticancer Drugs 2012; 23: 638-650.
29. Yang C, Yang Z, Zhang M, Dong Q, Wang X, Lan A, et al. Hydrogen sulfide protects against chemical hypoxia-induced cytotoxicity and inflammation in HaCaT cells through inhibition of ROS/NF-κB/COX-2 pathway. PLoS One 2011; 6: e21971.
30. Yang C, Ling H, Zhang M, Yang Z, Wang X, Zeng F, et al. Oxidative stress mediates chemical hypoxia-induced injury and inflammation by activating NF-kappaB-COX-2 pathway in HaCaT cells. J Mol Cells 2011; 31: 531-538.
31. Jiang H, Xia D, Wu LJ, Chen ZD. Inhibition of Bcl-2 enhances the efficacy of epirubicin chemotherapy in PC-3 prostate cancer cells. Chin Med J 2011; 124: 4018-4021.
32. Zexiang H, Xiaoyong L, Miao Z, Zhu B, Tang S, Liao D. Bcl-2 Small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma A549/DDP cell to cisplatin and diallyl disulfide. J Acta Biochim Biophys Sin 2007; 39: 835-843.